8-K: Sight Sciences secures $34M award, 10% Hydrus royalty

A Delaware court preserved Sight Sciences’ willful infringement verdict against Alcon, awarding $34M plus interest and a 10% Hydrus royalty through November 2028.

Summary

• On March 27, 2026, the U.S. District Court for the District of Delaware preserved the jury’s willful infringement verdict against Alcon’s Hydrus Microstent across U.S. Patents 8,287,482; 9,370,443; and 11,389,328.
• The order awards $34.0 million in past damages—$5.5 million in lost profits and $28.5 million in royalty damages—plus pre- and post-judgment interest and supplemental damages to be calculated.
• An ongoing royalty of 10% of Hydrus revenue applies from entry of final judgment through November 10, 2028, the expiration of the last asserted patent.
• A final judgment is expected in the coming months after Alcon provides supplemental financial data to calculate supplemental damages and pre-judgment interest; the final judgment is subject to appeal by Alcon.
• No monetary damages will be recovered until Alcon exhausts its appeal rights or the appeal period lapses.
• Alcon filed ex parte reexamination petitions at the USPTO in June 2025 challenging the asserted claims; adverse, final outcomes ahead of a final litigation judgment could negatively affect recovery.
• The USPTO denied Alcon’s inter partes review petitions on two of the asserted patents in March 2023.
• Sight Sciences expects to record a $5.4 million success fee to operating expenses payable to Cooley LLP, which it plans to exclude from non-GAAP adjusted operating expenses.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a materially positive legal milestone with clear economic potential, tempered by appeal and USPTO reexamination risks that delay and could jeopardize ultimate recovery.

Positives

• Court preserved the jury’s willful infringement verdict on all three asserted patents.
• $34.0 million in past damages awarded, with potential incremental supplemental damages and interest to be determined.
• A 10% ongoing royalty on Hydrus revenue through November 10, 2028 provides potential multi-year recurring economics if upheld.
• USPTO denial of Alcon’s IPR petitions in March 2023 supports the strength of the asserted patents.

Negatives

• Final judgment remains subject to appeal, and cash proceeds are not collectible until appeals conclude or the appeal window closes.
• Ongoing USPTO ex parte reexaminations could, if adversely and finally decided before a favorable final litigation judgment, impair the ability to collect on the award.
• A $5.4 million legal success fee will increase GAAP operating expenses in the near term.

Risks

• Appeal risk: Alcon can appeal the final judgment, potentially delaying, reducing, or overturning the award.
• USPTO ex parte reexamination risk: an adverse, final and non-appealable outcome before a final, non-appealable litigation judgment could negatively affect collection of damages and royalties.
• Timing risk: final judgment will only be entered after supplemental damages and pre-judgment interest are calculated based on Alcon’s supplemental financial data, leaving the payment timeline uncertain.

Future Outlook

Management expects a final judgment in the coming months after supplemental damages and pre-judgment interest are calculated from Alcon’s financial data; if upheld on appeal, Sight Sciences anticipates a 10% ongoing royalty on Hydrus revenue through November 10, 2028, while acknowledging that appeals and USPTO ex parte reexaminations could affect timing and recoverability.

Management Comments

• CEO Paul Badawi emphasized the importance of safeguarding the company’s intellectual property in interventional glaucoma and stated that protecting IP enables continued investment in a pipeline of interventional innovations to elevate the standard of care.

Industry Context

StockSavvy.ai notes that sustained IP enforcement is a key competitive lever in medical devices, particularly in microinvasive glaucoma surgery where Hydrus (Alcon) competes with Sight Sciences’ OMNI platform. A 10% royalty, if upheld, could reshape economics for a leading MIGS implant category participant and underscores the rising strategic value of defensible IP in ophthalmic devices.

Comparison to Industry Standards

• This announcement pertains to a legal ruling rather than operating performance; direct comparison to industry operating benchmarks (growth, margins) is not applicable.
• The 10% ongoing royalty sits at the upper end of typical publicly discussed medtech patent royalty ranges, indicating potentially meaningful economic impact if the judgment is upheld.

Legal Proceedings

• Delaware District Court order dated March 27, 2026 preserved the jury’s willful infringement verdict against Alcon’s Hydrus Microstent and awarded $34.0 million in past damages plus interest and supplemental damages, with a 10% ongoing royalty through November 10, 2028.
• Alcon’s June 2025 USPTO ex parte reexamination petitions challenging the asserted claims are ongoing; adverse, final outcomes before a final litigation judgment could impair recovery.
• USPTO denied Alcon’s inter partes review petitions on two asserted patents in March 2023.

Stakeholder Impact

• Shareholders: potential cash award and multi-year royalty stream, though timing and ultimate recovery remain uncertain due to appeals and USPTO reexaminations.
• Financials: a $5.4 million legal success fee will increase GAAP operating expenses near term (excluded from non-GAAP adjusted operating expenses).
• Competitive dynamics: if upheld, ongoing royalties on Hydrus could influence pricing and competitive strategies within the MIGS market.

Next Steps

• Calculate supplemental damages and pre-judgment interest after Alcon provides supplemental financial data.
• Court to enter final judgment in the coming months.
• Potential appeal by Alcon following entry of final judgment.
• Implement 10% ongoing royalty payments on Hydrus revenue post-final judgment through November 10, 2028, subject to appeals.
• Record and pay a $5.4 million success fee to Cooley LLP and exclude it from non-GAAP adjusted operating expenses.
• Continue to defend asserted patent claims in USPTO ex parte reexaminations and any related appeals.

Key Dates

Recommendation

A meaningful legal win with defined monetary damages and a high 10% royalty rate offers upside, but collection is contingent on a final, non-appealable judgment and could be undermined by ongoing USPTO ex parte reexaminations. Given timing and outcome uncertainty alongside near-term legal expenses, maintaining a hold stance is prudent pending appellate and USPTO resolution.

Keywords

patent litigation, Hydrus Microstent, Alcon, willful infringement, ongoing royalty, glaucoma, microinvasive glaucoma surgery, Sight Sciences, OMNI Surgical System, USPTO reexamination, IPR denial, royalty damages, lost profits, ophthalmology devices